Ebola Drug Developed With Government Funding
International Business Times
Published Aug 07, 2014 10:35AM ET
Ebola Drug Developed With Government Funding
By Meagan Clark - The experimental drug being used to treat two Americans stricken with the Ebola virus while treating patients in Africa was funded in large part by the same U.S. Department of Defense unit that developed the Internet. Kentucky BioProcessing, acquired by cigarette-maker Reynolds American Inc. NYSE:RAI in January, received millions of dollars from the U.S. Defense Department to develop the medicine that may save the lives of missionaries Nancy Writebol and Dr. Kent Brantly.
In 2010, the company received a one-year, $17.9 million contract with the Defense Advanced Research Projects Agency (DARPA) to produce “a proof-of-concept platform capable of yielding a purified vaccine candidate using a whole plant-based process,” with an expected completion date of March 2011, according to the contract.
DARPA was created in 1958 as the Advanced Research Projects Agency (ARPA) to design and execute cutting edge technology. Among its most notable creations are the Internet, stealth plane technology and the U.S. military's m16 assault rifle.
For the Ebola virus treatment, Kentucky BioProcessing made the drug cocktail called ZMapp for the San Diego-based lab Mapp Biopharmaceutical. ZMapp is a combination of Ebola treatments that contains three antibodies meant to fight the virus once. Scientists took the antibodies from mice exposed to Ebola and genetically altered a tobacco plant strain to produce the antibodies.
Only Kentucky BioProcessing is authorized by the U.S. government to produce ZMapp, and currently, only a handful of doses are available, director of National Institute of Allergy and Infectious Diseases, Anthony Fauci, told CNN Tuesday.
Some are asking if the drug, which may or may not be responsible for Writebol and Brantly’s improving conditions, could be given to the hundreds of Africans dying of Ebola in Liberia, Sierra Leone, Guinea and Nigeria. But after three decades of research and millions of U.S. government dollars flowing to various labs, it would still take months to produce more doses of ZMapp, the Washington Post reported. Four to five other Ebola vaccines are on pace for early-stage human trials this fall, all with years of research and government grants behind them, according to the newspaper.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.